Simvastatin and Rifaximin Combination Therapy to Manage Decompensated Liver Cirrhosis
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on April 18th, 2025
|
Decompensated liver cirrhosis represents the most advanced stage of liver damage, marked by extensive scarring and significantly reduced liver function. This condition can ultimately progress to acute liver failure and death, and there are currently no therapies available to prevent its progression. Funded by the European Union, a study was conducted to evaluate the use of simvastatin and rifaximin in managing liver cirrhosis.
The phase 3 clinical trial enrolled 237 participants with an average age of approximately 57, all diagnosed with decompensated cirrhosis (Child-Pugh class B or C). In 80% of these patients, liver disease was primarily attributed to alcohol consumption, while metabolic causes and infections such as hepatitis B and C were the next most common factors. To manage their condition, around 50% of the patients were treated with lactulose and beta blockers, whereas norfloxacin was used in only about 10% of cases.
Patients were randomly assigned to receive either an oral placebo or a combination treatment of simvastatin and rifaximin. In the treatment group, simvastatin was administered daily at a dose of 20 mg, while rifaximin was given at 400 mg three times per day. Simvastatin works by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, which lowers serum cholesterol levels and exerts anti-inflammatory effects that help alleviate liver and systemic inflammation associated with cirrhosis. Rifaximin, a minimally absorbed antibiotic that remains concentrated in the intestinal lumen, was used to address gut dysbiosis and increased mucosal permeability—factors linked to cirrhosis and the development of hepatic encephalopathy—by modulating the gut microbiome and counteracting these detrimental effects.
After 12 months of treatment, the researchers found that the combination of simvastatin and rifaximin did not reduce the risk of progressing to liver failure. Moreover, the treatment did not lower the risks of death, transplantation, or other complications such as ascites and hepatic encephalopathy. The investigators suggested that this lack of efficacy might be due to the relatively low dose of simvastatin, which is at the lower end of the effective range for lipid-lowering. They also noted that the study population was predominantly composed of patients with moderate to severe liver dysfunction and alcohol-related cirrhosis. Future studies could examine the effects of this treatment in populations with less advanced cirrhosis, particularly those driven by infectious or metabolic causes.
The phase 3 clinical trial enrolled 237 participants with an average age of approximately 57, all diagnosed with decompensated cirrhosis (Child-Pugh class B or C). In 80% of these patients, liver disease was primarily attributed to alcohol consumption, while metabolic causes and infections such as hepatitis B and C were the next most common factors. To manage their condition, around 50% of the patients were treated with lactulose and beta blockers, whereas norfloxacin was used in only about 10% of cases.
Patients were randomly assigned to receive either an oral placebo or a combination treatment of simvastatin and rifaximin. In the treatment group, simvastatin was administered daily at a dose of 20 mg, while rifaximin was given at 400 mg three times per day. Simvastatin works by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, which lowers serum cholesterol levels and exerts anti-inflammatory effects that help alleviate liver and systemic inflammation associated with cirrhosis. Rifaximin, a minimally absorbed antibiotic that remains concentrated in the intestinal lumen, was used to address gut dysbiosis and increased mucosal permeability—factors linked to cirrhosis and the development of hepatic encephalopathy—by modulating the gut microbiome and counteracting these detrimental effects.
After 12 months of treatment, the researchers found that the combination of simvastatin and rifaximin did not reduce the risk of progressing to liver failure. Moreover, the treatment did not lower the risks of death, transplantation, or other complications such as ascites and hepatic encephalopathy. The investigators suggested that this lack of efficacy might be due to the relatively low dose of simvastatin, which is at the lower end of the effective range for lipid-lowering. They also noted that the study population was predominantly composed of patients with moderate to severe liver dysfunction and alcohol-related cirrhosis. Future studies could examine the effects of this treatment in populations with less advanced cirrhosis, particularly those driven by infectious or metabolic causes.